CellaVision (CEVI.ST) Stock Price
CellaVision Price
Over the last 19 years CellaVision grew revenue by 14.8% annually, reaching 758.97 M SEK. Earnings per share have grown at 25.3% per year over the last 18 years. For CellaVision, the net margin of 20.2% is down versus 22.2% a few years ago. At today's price the dividend yield works out to roughly 1.47%. The payout ratio is around 39% of earnings. The dividend has grown at 15.1% per year over the past 13 years. The consensus 12-month price target for CellaVision is 232.56 SEK, about 36.3% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 44% above its 52-week low.
CellaVision stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of CellaVision over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how CellaVision stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing CellaVision's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | CellaVision Price |
|---|---|
| 9/25/2026 | 170.60 SEK |
| 9/22/2026 | 166.40 SEK |
| 9/21/2026 | 166.80 SEK |
| 9/18/2026 | 165.80 SEK |
| 9/17/2026 | 165.00 SEK |
| 9/16/2026 | 162.40 SEK |
| 9/15/2026 | 160.00 SEK |
| 9/14/2026 | 161.80 SEK |
| 9/11/2026 | 161.40 SEK |
| 9/10/2026 | 158.20 SEK |
| 9/9/2026 | 160.60 SEK |
| 9/8/2026 | 162.20 SEK |
| 9/7/2026 | 163.60 SEK |
| 9/4/2026 | 160.40 SEK |
| 9/3/2026 | 162.60 SEK |
| 9/2/2026 | 163.60 SEK |
| 9/1/2026 | 164.60 SEK |
| 8/31/2026 | 165.80 SEK |
| 8/28/2026 | 164.40 SEK |
| 8/27/2026 | 163.60 SEK |
| 8/26/2026 | 164.00 SEK |
| 8/25/2026 | 164.00 SEK |
| 8/21/2026 | 163.60 SEK |
| 8/20/2026 | 162.20 SEK |
| 8/19/2026 | 154.60 SEK |
| 8/17/2026 | 151.40 SEK |
| 8/14/2026 | 152.80 SEK |
| 8/13/2026 | 152.40 SEK |
| 8/12/2026 | 154.80 SEK |
| 8/11/2026 | 154.80 SEK |
CellaVision Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
CellaVision Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM SEK |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM SEK |
| EBITM SEK |
| EBIT MARGIN% |
| NET INCOMEM SEK |
| NET INCOME GROWTH% |
| DIVIDENDDIV.SEK |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 179.00 | 216.00 | 239.00 | 265.00 | 309.00 | 364.00 | 461.00 | 471.00 | 565.00 | 639.00 | 677.00 | 723.00 | 758.00 | 775.00 | 870.00 | 944.00 |
| 5.92 | 20.67 | 10.65 | 10.88 | 16.60 | 17.80 | 26.65 | 2.17 | 19.96 | 13.10 | 5.95 | 6.79 | 4.84 | 2.24 | 12.26 | 8.51 |
| 62.57 | 67.13 | 72.80 | 70.94 | 72.17 | 74.18 | 72.89 | 66.45 | 69.38 | 68.54 | 68.39 | 67.36 | 68.47 | 68.47 | 68.47 | 68.47 |
| 112.00 | 145.00 | 174.00 | 188.00 | 223.00 | 270.00 | 336.00 | 313.00 | 392.00 | 438.00 | 463.00 | 487.00 | 519.00 | 530.64 | 595.69 | 646.35 |
| 25.00 | 42.00 | 65.00 | 67.00 | 90.00 | 111.00 | 127.00 | 110.00 | 162.00 | 158.00 | 167.00 | 177.00 | 202.00 | 185.00 | 227.00 | 256.00 |
| 13.97 | 19.44 | 27.20 | 25.28 | 29.13 | 30.49 | 27.55 | 23.35 | 28.67 | 24.73 | 24.67 | 24.48 | 26.65 | 23.87 | 26.09 | 27.12 |
| 18.00 | 31.00 | 52.00 | 59.00 | 69.00 | 88.00 | 99.00 | 89.00 | 125.00 | 118.00 | 130.00 | 140.00 | 153.00 | 141.00 | 174.00 | 197.00 |
| 200.00 | 72.22 | 67.74 | 13.46 | 16.95 | 27.54 | 12.50 | -10.10 | 40.45 | -5.60 | 10.17 | 7.69 | 9.29 | -7.84 | 23.40 | 13.22 |
| 0.40 | 0.50 | 1.00 | 1.50 | 1.50 | 1.50 | 1.50 | – | 0.75 | 2.00 | 2.25 | 2.25 | 2.50 | 2.75 | 3.30 | 3.96 |
| – | 25.00 | 100.00 | 50.00 | – | – | – | – | – | 166.67 | 12.50 | – | 11.11 | 10.00 | 20.00 | 20.00 |
| 23.85 | 23.85 | 23.85 | 23.85 | 23.85 | 23.85 | 23.85 | 23.85 | 23.85 | 23.85 | 23.87 | 23.85 | 23.85 | 23.85 | 23.85 | 23.85 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales CellaVision generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CellaVision retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CellaVision's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares CellaVision has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CellaVision's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
CellaVision stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
CellaVision Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
CellaVision business model & stock analysis
CellaVision SWOT Analysis
Strengths
1. Technological Expertise: CellaVision AB has built a strong reputation in the market for its advanced technologies in digital microscopy and image analysis.
2. High Quality Products: The company offers high-quality automated hematology analyzers and related software solutions, ensuring accuracy and reliability for its customers.
3. Strong Market Presence: CellaVision AB has established a dominant position in the global hematology market, providing innovative solutions to healthcare institutions worldwide.
Weaknesses
1. Limited Product Portfolio: The company's product portfolio predominantly focuses on hematology analysis, which leaves it vulnerable to market fluctuations and lack of diversification.
2. Dependence on Key Customers: CellaVision AB relies on a few major customers for a significant portion of its revenue, exposing it to potential risks if these relationships deteriorate.
3. Intense Competition: The industry is highly competitive, with several global players vying for market share. CellaVision AB needs to continuously innovate and adapt to maintain its competitive edge.
Opportunities
1. Growing Healthcare Market: The increasing demand for efficient and advanced hematology analyzers presents an opportunity for CellaVision AB to expand its customer base.
2. Emerging Markets: The company can explore untapped markets in developing countries where the adoption of automated hematology analyzers is on the rise.
3. Technological Advancements: Continual advancements in imaging and analysis technologies open doors for CellaVision AB to develop innovative solutions and capture new market segments.
Threats
1. Regulatory Challenges: Changing regulations and compliance requirements in the healthcare industry may pose challenges for CellaVision AB, leading to increased costs and restricted market access.
2. Economic Volatility: Uncertain economic conditions could impact healthcare budgets, potentially reducing the demand for CellaVision AB's products.
3. Technological Obsolescence: Rapid technological advancements could render current products obsolete, necessitating constant investment in research and development to stay ahead.
CellaVision Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
CellaVision historical P/E ratio, EBIT multiple, and P/S ratio
CellaVision annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down CellaVision's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in CellaVision's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare CellaVision's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
CellaVision shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
CellaVision Dividend History
14 years of dividend payments
CellaVision dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
CellaVision dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current CellaVision forecasts and price targets in September 2026
Analyst Price Targets 2026CellaVision Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 10/28/2026 | 1.45SEK | - | 190.17 MSEK | - | 2026 Q3 |
| 7/17/2026 | 1.34SEK | 1.37SEK | 184.15 MSEK | - | 2026 Q2 |
| 4/24/2026 | 1.54SEK | 0.94SEK | 190.43 MSEK | - | 2026 Q1 |
| 2/5/2026 | 1.31SEK | 1.80SEK | 191.98 MSEK | - | 2025 Q4 |
| 11/6/2025 | 1.06SEK | 1.31SEK | 178.08 MSEK | - | 2025 Q3 |
| 7/18/2025 | 1.65SEK | 1.60SEK | 191.50 MSEK | - | 2025 Q2 |
| 4/28/2025 | 1.38SEK | 1.70SEK | 174.98 MSEK | - | 2025 Q1 |
| 2/5/2025 | 1.93SEK | 1.70SEK | 202.53 MSEK | - | 2024 Q4 |
| 10/24/2024 | 1.70SEK | 1.30SEK | 188.20 MSEK | - | 2024 Q3 |
| 7/19/2024 | 1.70SEK | 1.62SEK | 189.38 MSEK | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the CellaVision stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
CellaVision shareholder structure
| % | Name |
|---|---|
2.92834% | |
1.75444% | |
1.70760% | |
1.67538% | |
1.58080% | |
1.48837% |
CellaVision Beneficial Ownership Filings (SEC 13D/G)
CellaVision Executives and Management Board
17 members · avg. age 51 · 35 % women
Mr. Simon Oestergaard (53)
President, Chief Executive Officer
6.57 M SEK
Management
Ms. Monica Joensson (45)
Interim Chief Financial Officer
Mr. Urban Strindloev (60)
Vice President - Global Sales
Ms. Elin Bredberg (46)
Vice President of Human Resources
Mr. Adam Morell (48)
Vice President - Devices & Software Division · since 2021
Ms. Charlotte Oom (45)
Vice President - Quality, Clinical and Regulatory Affairs
Mr. Julien Veyssy (41)
Vice President - Reagents Division
Board of Directors
Mr. Mikael Worning (62)
Independent Chairman of the Board
Ms. Ann-Charlotte Jarleryd (59)
Independent Director
Dr. Christer Fahraeus (60)
Director, Founder · since 1998
Ms. Louise Armstrong- Denby (52)
Independent Director
Mr. Stefan Wolf (60)
Independent Director
Mr. Emil Hjalmarsson (36)
Director
Frequently asked questions about CellaVision
The business model of CellaVision AB focuses on developing and selling digital solutions for medical laboratories worldwide. CellaVision offers an innovative range of products, including automated digital systems for advanced blood cell analysis and software solutions for efficient lab management. The company's solutions aim to improve lab productivity, quality, and patient care by streamlining workflow processes and enhancing the accuracy of blood cell analysis. CellaVision AB stands as a leading provider in the field of hematology diagnostics, enabling healthcare professionals to make better-informed decisions for optimizing patient outcomes.
CellaVision AB is primarily active in the medical technology industry.
The main competitors of CellaVision AB in the market include Sysmex Corporation, Roche Diagnostics, and Beckman Coulter.
CellaVision AB is a leading global provider of advanced digital solutions for medical microscopy in the field of hematology. Founded in 1994, CellaVision has a rich history in developing and supplying innovative products that revolutionize the analysis of blood and other body fluids. The company's breakthrough technologies enable automated digital microscopy, accelerating and improving the diagnostic workflow in clinical laboratories. CellaVision's solutions offer healthcare professionals increased efficiency, accuracy, and patient safety, ultimately contributing to better healthcare outcomes. With a strong commitment to research and development, CellaVision continues to pioneer advancements in digital hematology, establishing itself as a trusted name in the industry.
CellaVision AB, a renowned company in the stock market, has achieved several significant milestones throughout its journey. These include the development and launch of cutting-edge hematology analyzers, such as the CellaVision DM96 and CellaVision DC-1. The company has also expanded its global presence, establishing strategic partnerships with various leading healthcare organizations worldwide. Furthermore, CellaVision AB has consistently demonstrated its commitment to innovation by continuously enhancing its product portfolio and introducing advanced digital solutions in the field of automated blood and body fluid analysis. With its relentless pursuit of excellence and industry recognition, CellaVision AB stands as a remarkable player in the stock market.
CellaVision AB is primarily present in various countries and regions around the world. With its global reach, the company has established its presence in countries such as Sweden, the United States, and various European and Asian markets. CellaVision AB's extensive global footprint allows it to cater to a diverse customer base and expand its market share internationally.
CellaVision AB represents a set of core values and a corporate philosophy that underpin its operations. The company is committed to excellence, innovation, and customer satisfaction. Through its cutting-edge technologies and solutions, CellaVision aims to revolutionize hematology analysis and improve patient care. With a focus on quality, CellaVision strives to deliver accurate and reliable results, empowering healthcare professionals worldwide. Moreover, the company fosters a culture of collaboration, teamwork, and transparency to drive advancements in the field of medical diagnostics. By embodying these values, CellaVision AB remains dedicated to its mission of transforming healthcare through intelligent automation and efficient laboratory workflows.
Analysts currently set an average price target of 223.72 SEK for the CellaVision stock (median: 232.56 SEK), implying +34.4 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the CellaVision stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect CellaVision to generate revenue of 775.10 M SEK and earnings per share of 5.93 SEK.
Converted at the current exchange rate, the CellaVision share trades at 15.12 EUR (170.60 SEK).
The CellaVision share (CEVI.ST) is listed on 5 stock exchanges, including: London (0MR5.L), Frankfurt (C26.F), München (C26.MU), Stockholm (CEVI.ST).
CellaVision AB is a leading provider of digital solutions for automated blood cell analysis. The company, based in Lund, Sweden, was founded in 1994 and now employs over 350 people.
The expected revenue of CellaVision is 775.10 M SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of CellaVision is 141.44 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of CellaVision is currently 28.77. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CellaVision stock.
The price-to-sales ratio (P/S) of CellaVision is currently 5.25. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CellaVision stock.
The Eulerpool Quality Score for CellaVision is 8/10.
The ISIN of CellaVision is SE0000683484. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of CellaVision is A0NEVD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of CellaVision is CEVI.ST. The ticker symbol is used to trade CellaVision shares on the stock exchange.
Over the past 12 months, CellaVision paid a dividend of 2.50 SEK . This corresponds to a dividend yield of about 1.47 %. For the coming 12 months, CellaVision is expected to pay a dividend of 3.30 SEK.
The current dividend yield of CellaVision is 1.47 %.
CellaVision pays a dividend, distributed in the months of May, April.
CellaVision paid dividends every year for the past 5 years.
For the upcoming 12 months, dividends amounting to 3.30 SEK are expected. This corresponds to a dividend yield of 1.98 %.
CellaVision is assigned to the 'Health' sector.
To receive the latest dividend of CellaVision from 5/6/2026 amounting to 2.75 SEK, you needed to have the stock in your portfolio before the ex-date on 4/29/2026.
The last dividend was paid out on 5/6/2026.
In the year 2025, CellaVision distributed 2.5 SEK as dividends.
The dividends of CellaVision are distributed in SEK.
CellaVision stock
CellaVision Peer Group
CellaVision Ticker
CellaVision FIGI
All fundamentals and in-depth analysis of CellaVision
Our stock analysis for CellaVision stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CellaVision. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.